Parkinson's Disease - Market to grow as first round of lifecycle management strategies succeed

"IntroductionThe PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro.ScopeAnalysis of patient potential, unmet needs and clinical trial design in PD Overview of key marketed brands, late- and early-stage pipeline drugs, and cell/gene therapies. Indication- and country-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs. Identification of future market events that are expected to affect PD drug revenues.HighlightsGSK's Requip Modutab will become the market leading PD brand in 2011. It will be intuitive for prescribers to believe that sustained activation of dopamine receptors with Requip Modutab could have a significant clinical benefit over pulsed agonism with standard drugs. New pipeline drugs will need to be innovative to compete in an increasingly crowded market. While this is evident in Eisai's E2007, it is lacking in Merck-Serono/Newron's safinamide. Early studies with cell/gene therapies show great promise for significantly slowing the progression of the disease. However, these alternative approaches will not significantly impact the sales of pharmaceuticals over the forecast period 20072016.Reasons to PurchaseBenchmark key late-stage PD compounds against current market leading brands. Assess country-specific (US, Japan, France, Germany, Italy, Spain and the UK) sales forecasts of key late-stage pipeline drugs and marketed brands. Understand unmet needs and opportunities in the PD market based on key opinion leader comments."

28-Sep-07 Format: PDF & DataPack Pages: 244
Table of Contents
Price: $15,200.00 / GBP7,600.00